Theseus Pharmaceuticals lays off most workers and seeks ‘strategic alternatives’ after cancer pipeline failurenews2023-11-14T07:57:04+00:00November 14th, 2023|Endpoints News|
Swiss cancer vaccine biotech Nouscom raises $72M Series C for PhII trialsnews2023-11-14T06:00:01+00:00November 14th, 2023|Endpoints News|
Orbital Therapeutics closes South San Francisco lab, eliminating some rolesnews2023-11-13T21:41:44+00:00November 13th, 2023|Endpoints News|
Ipsen, Genfit unveil additional PhIII data for rare liver disease drug, further boosting regulatory ambitionnews2023-11-13T21:30:10+00:00November 13th, 2023|Endpoints News|
Japan considers adjusting clinical trial requirements to remove the need for local studies — reportnews2023-11-13T20:49:21+00:00November 13th, 2023|Endpoints News|
FDA explains why it denied about 60% of non-oncology breakthrough therapy requests from 2017 to 2019news2023-11-13T19:47:54+00:00November 13th, 2023|Endpoints News|
Michigan to repeal pharma industry’s legal liability shield from 1995news2023-11-13T18:59:49+00:00November 13th, 2023|Endpoints News|
GSK raises rare blood cancer awareness with well-known ‘Queer Eye’ designernews2023-11-13T18:40:50+00:00November 13th, 2023|Endpoints News|
BridgeBio eyes US filing for ATTR-CM drug after new PhIII data show ‘fastest’ clinical benefit to datenews2023-11-13T16:27:41+00:00November 13th, 2023|Endpoints News|
Anthos’ blood thinner cuts the risk of bleeding amid race to develop safer anticoagulantsnews2023-11-13T16:12:06+00:00November 13th, 2023|Endpoints News|
